Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

381

Participants

Timeline

Start Date

April 16, 2019

Primary Completion Date

April 8, 2027

Study Completion Date

April 8, 2027

Conditions
Multiple Myeloma
Interventions
BIOLOGICAL

bb2121

bb2121

DRUG

Daratumumab

Daratumumab

DRUG

Pomalidomide

Pomalidomide

DRUG

Dexamethasone

Dexamethasone

DRUG

Bortezomib

Bortezomib

DRUG

Ixazomib

Ixazomib

DRUG

Lenalidomide

Lenalidomide

DRUG

Carfilzomib

Carfilzomib

DRUG

Elotuzumab

Elotuzumab

Trial Locations (60)

3000

Local Institution - 202, Leuven

3010

Local Institution - 251, Bern

10016

Local Institution - 109, Birmingham

10029

Local Institution - 119, New York

10065

Local Institution - 115, New York

Local Institution - 135, New York

15232

University of Pittsburgh Medical Center William M. Cooper Ambulatory Care Pavillion, Pittsburgh

19107

Local Institution - 111, Philadelphia

19111

Local Institution - 110, Philadelphia

20246

Local Institution - 514, Hamburg

27705

Local Institution - 113, Durham

30322

Local Institution - 131, Atlanta

30342

Local Institution - 140, Atlanta

31008

Local Institution - 750, Pamplona

31059

Local Institution - 401, Toulouse

32224

Local Institution - 108, Jacksonville

33612

Local Institution - 102, Tampa

37007

Local Institution - 751, Salamanca

37203

Local Institution - 106, Nashville

40138

Local Institution - 611, Bologna

40225

Local Institution - 513, Düsseldorf

44093

Local Institution - 403, Nantes

50937

Local Institution - 515, Cologne

53792

Local Institution - 107, Madison

59037

Local Institution - 402, Lille

60611

Local Institution - 139, Chicago

63110

Local Institution - 114, St Louis

69120

Local Institution - 512, Heidelberg

75010

Local Institution - 400, Paris

75246

Local Institution - 118, Dallas

75390

Local Institution - 103, Dallas

77030

Local Institution - 132, Houston

80045

Local Institution - 142, Aurora

84112

Local Institution - 136, Salt Lake City

85259

Local Institution - 141, Scottsdale

90048

Local Institution - 145, Los Angeles

90095

Local Institution - 122, Los Angeles

94304

Local Institution - 124, Palo Alto

97080

Local Institution - 511, Würzburg

98104

Local Institution - 105, Seattle

46202-528

Local Institution - 100, Indianapolis

66205-2003

Local Institution - 112, Westwood

21201-1595

Local Institution - 104, Baltimore

02114

Local Institution - 134, Boston

02215

Local Institution - 123, Boston

48109-5936

University Of Michigan Comprehensive Cancer Center, Ann Arbor

55905-0001

Local Institution - 125, Rochester

07601

Local Institution - 138, Hackensack

T2N 4N2

Local Institution - 302, Calgary

M5G 2M9

Local Institution - 303, Toronto

113-8677

Local Institution - 806, Bunkyō City

259-1193

Local Institution - 804, Isehara City, Kanagawa

467-8602

Local Institution - 807, Nagoya

150-8935

Local Institution - 805, Shibuya-ku

1081 HV

Local Institution - 650, Amsterdam

3015 CN

Local Institution - 651, Rotterdam

N-0027

Local Institution - 700, Oslo

SE-141 86

Local Institution - 800, Stockholm

LS9 7TF

Local Institution - 850, Leeds

SE5 9RS

Local Institution - 851, London

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Celgene

INDUSTRY

NCT03651128 - Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM) | Biotech Hunter | Biotech Hunter